Document:

EX-4.2

 Exhibit 4.2 
 REGADO BIOSCIENCES, INC. 
 THIRD AMENDED AND RESTATED INVESTORS’
RIGHTS AGREEMENT 
 This THIRD AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (the
“Agreement”) is made as of the 18th day
of December, 2012 by and among the persons listed as “Founders” on Schedule A hereto (each, a “Founder” and collectively, the “Founders”), the persons listed as “Common
Stockholders” on Schedule A hereto (each, a “Common Stockholder” and collectively, the “Common Stockholders”), Regado Biosciences, Inc., a Delaware corporation (the “Company”),
the holders of the Company’s Series A Preferred Stock (as defined below) listed on Schedule A hereto (individually, a “Series A Holder” and collectively, the “Series A Holders”), and the holders
of the Company’s Series B Preferred Stock (as defined below) listed on Schedule A hereto (individually, a “Series B Holder” and collectively, the “Series B Holders”), and the holders of the
Company’s Series C Preferred Stock (as defined below) listed on Schedule A hereto (individually, a “Series C Holder” and collectively, the “Series C Holders”), and the holders of the
Company’s Series D Preferred Stock (as defined below) listed on Schedule A hereto (individually, a “Series D Holder” and collectively, the “Series D Holders”), and the holders of the
Company’s Series E Preferred Stock (as defined below) listed on Schedule A hereto (individually, a “Series E Holder” and collectively, the “Series E Holders”, together with the Series A Holders,
the Series B Holders, the Series C Holders, and the Series D Holders, the “Preferred Holders”), amending and restating the Second Amended and Restated Investors’ Rights Agreement, made as of December 17, 2009 (the
“Second Amended and Restated Investors’ Rights Agreement”). The Founders, the Common Stockholders, the Series A Holders, the Series B Holders, the Series C Holders, the Series D Holders, and the Series E Holders are sometimes
collectively referred to as a “Stockholder” or the “Stockholders”. 
 RECITALS:

 WHEREAS, the Founders, the Common Stockholders, the Company, the Series A Holders, the Series B Holders, the Series C
Holders and the Series D Holders (i) previously entered into the Second Amended and Restated Investors’ Rights Agreement and (ii) desire to amend and restate the Second Amended and Restated Investors’ Rights Agreement; and

 WHEREAS, the Series E Holders and the Company are a party to that certain Series E Preferred Stock Purchase Agreement, dated
as of the date hereof (the “Purchase Agreement”), pursuant to which the Series E Holders acquired shares of Series E Preferred Stock of the Company; and 
 WHEREAS, in order to induce the Series E Holders to consummate the transactions contemplated by the Purchase Agreement, the Company is willing to grant certain rights under this Agreement with respect to
the shares of Series E Preferred Stock and the Stockholders are willing to amend and restate the Second Amended and Restated Investors’ Rights Agreement; 

 NOW, THEREFORE, in consideration of the mutual promises and covenants set forth in this
Agreement, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties, intending to be legally bound, agree as follows: 
 SECTION 1. DEFINITIONS. 
 1.1 “Aurora Funds” shall mean
Aurora Ventures IV, L.L.C. and Aurora Ventures V, LP. 
 1.2 “Common Stock” will mean the Company’s Common
Stock, par value $0.001 per share. 
 1.3 “Domain” shall mean Domain Partners VI, L.P. and DP VI Associates,
L.P. 
 1.4 “New Securities” means, collectively, equity securities of the Company, whether or not currently
authorized, as well as rights, options, or warrants to purchase such equity securities, or securities of any type whatsoever that are, or may become, convertible or exchangeable into or exercisable for such equity securities. 

1.5 “Preferred Shares” will mean the Company’s Series A Preferred, Series B Preferred, Series C Preferred, Series D
Preferred and Series E Preferred Stock. 
 1.6 “Quaker Partners” shall mean Quaker Bioventures, L.P.

 1.7 “RMI” shall mean RMI Investments, S.a.r.l 

1.8 “Secondary Refusal Right” means the right, but not an obligation, of the Company to purchase all or part of the
Shares covered in the Notice delivered pursuant to Section 2.1 below not purchased by the Purchasing Participants, on the terms and conditions specified in the Notice. 
 1.9 “Series A Preferred” will mean the Company’s Series A Preferred Stock, par value $0.001 per share. 
 1.10 “Series B Preferred” will mean the Company’s Series B Preferred Stock, par value $0.001 per share. 
 1.11 “Series C Preferred” will mean the Company’s Series C Preferred Stock, par value $0.001 per share. 
 1.12 “Series D Preferred” will mean the Company’s Series D Preferred Stock, par value $0.001 per share. 
 1.13 “Series E Preferred” will mean the Company’s Series E Preferred Stock, par value $0.001 per share. 
 1.14 “Shares” will mean shares of the Company’s Common Stock, Series A Preferred, Series B Preferred, Series C Preferred, Series D Preferred or Series E Preferred now owned or
subsequently acquired by the Stockholders. 
 SECTION 2. SALES OR TRANSFERS OF STOCK OF THE COMPANY. 

2.1 Notice of Sales or Transfers. 

  
 - 2 -

 If any Founder, Common Stockholder or Preferred Holder proposes to sell or transfer to a
third party or parties (a “Third Party Purchaser”) any Shares in one transaction or a series of related transactions (each, a “Selling Stockholder”), then such Selling Stockholder will promptly give written notice
(the “Notice”) to the Company and the Preferred Holders at least thirty (30) days prior to the closing of such sale or transfer. The Notice will describe in reasonable detail the proposed sale or transfer including, without
limitation, the number of Shares to be sold or transferred, the nature of such sale or transfer, the consideration to be paid, and the name and address of each Third Party Purchaser or transferee. In the event that the sale or transfer is being made
pursuant to the provisions of Section 3 hereof, the Notice will state under which paragraph and subparagraph the sale or transfer is being made. 
 2.2 Right of First Refusal. 
 (a) The Preferred Holders will have the
right, exercisable upon written notice to the Selling Stockholder within fifteen (15) days after receipt of the Notice, to elect to purchase all or any part of the Shares covered in the Notice directly from the Selling Stockholder, on the same
terms and conditions specified in the Notice. If any Preferred Holder fails to elect to fully purchase his pro rata portion of the unsold Shares pursuant to Section 2.2(a), the Selling Stockholder will give notice (the
“Undersubscription Notice”) of such failure to the Preferred Holders who did so elect (the “Purchasing Participants”). Such Undersubscription Notice may be made by telephone if confirmed in writing within
forty-eight (48) hours. The Purchasing Participants will have five (5) days from the date such Undersubscription Notice was received to agree to acquire their pro rata share of the unsold portion. For purposes of this Section 2.2(a),
a Purchasing Participant’s pro rata share will be equal to the product obtained by multiplying (i) the aggregate number of Shares in the unsold portion covered by the notice by (ii) a fraction, the numerator of which is the number of
shares of Preferred Shares held by such Purchasing Participant and the denominator of which is the total number of Preferred Shares owned by all Purchasing Participants. 
 (b) Subject to the terms of Section 2.2(a) above and subject to the approval of a supermajority of the Company’s Board of Directors, each Selling Stockholder hereby grants to the Company a
Secondary Refusal Right to purchase all or any part of the Shares covered by the Notice not purchased by the Purchasing Participants pursuant to Section 2.2(a). If the Purchasing Participants fail to elect to fully purchase the Shares covered
by the Notice, the Selling Stockholder must deliver prompt written notice (the “Secondary Notice”) to the Company to that effect no later than fifteen (15) days after the Selling Stockholder delivers the Undersubscription
Notice to the Purchasing Participants. To exercise its Secondary Refusal Right, the Company must deliver to the Selling Stockholder within ten (10) days after receipt of the Secondary Notice, written notice of its intention to purchase all or
any part of the unsold Shares covered by the Notice directly from the Selling Stockholder, on the same terms and conditions specified in the Notice. 
 (c) To the extent that any Purchasing Participant or the Company as provided in this Section 2.2 elects to purchase all or a portion of the Shares covered in the Notice directly from the Selling
Stockholder and subject to Section 2.2(d), then such Selling Stockholder will deliver certificate(s), properly endorsed for transfer, representing such Shares to such Purchasing Participant or the Company who will deliver to the Selling
Stockholder the consideration of the type and on the terms set forth in the Notice. 

  
 - 3 -

 (d) At the conclusion of the procedures outlined in Section 2.2(a) and
Section 2.2(b), if the Preferred Holders and the Company have declined to purchase any remaining unsold portion of Shares on the terms set forth in the Notice, the Selling Stockholder will send a second notice (the “Co-Sale
Notice”) to all Preferred Holders notifying them of the right of co-sale of each Preferred Holder other than the Purchasing Participants under Section 2.3 of this Agreement. 

2.3 Right of Co-Sale. 
 (a) In the event that less than all Shares described in the Notice have been purchased in accordance with Section 2.2 above, each Preferred Holder other than the Purchasing Participants will have the
right, exercisable upon written notice to the Selling Stockholder within ten (10) days after the receipt of the Co-Sale Notice described in Section 2.2(d) above, to co-sell Shares with the Selling Stockholder to the Third Party Purchaser,
on the same terms and conditions specified in the Notice. To the extent that one or more of the Preferred Holders other than the Purchasing Participants exercise such right in accordance with the terms and conditions set forth below, the number of
Shares that the Selling Stockholder may sell in the transaction will be correspondingly reduced. 
 (b) Each Preferred Holder
other than the Purchasing Participants may sell all or any part of that number of Shares held by him equal to the product obtained by multiplying (i) the aggregate number of Shares covered by the Co-Sale Notice described in Section 2.2(d)
above by (ii) a fraction, the numerator of which is the number of shares of Preferred Shares held by such Preferred Holder and the denominator of which is the total number of Preferred Shares owned by all Preferred Holders other than the
Purchasing Participants at the time of the sale or transfer. 
 (c) If any Preferred Holder fails to elect to fully participate
in such sale on a co-sale basis pursuant to this Section 2.3, the Selling Stockholder will give notice of such failure to the Preferred Holders who did so elect (the “Selling Participants”). Such notice may be made by telephone
if confirmed in writing within forty-eight (48) hours. The Selling Participants will have five (5) days from the date such notice was received to agree to sell their pro rata share of the unsold portion. For purposes of this
Section 2.3(c), a Selling Participant’s pro rata share will be equal to the product obtained by multiplying (i) the aggregate number of Shares in the unsold portion covered by the notice by (ii) a fraction, the numerator of which
is the number of shares of Preferred Shares held by such Selling Participant and the denominator of which is the total number of Preferred Shares owned by all Selling Participants. 

(d) Each Selling Participant will effect its co-sale participation in a sale by promptly delivering to the Selling Stockholder for
transfer to the Third Party Purchaser one or more certificates, properly endorsed for transfer, which represents that number of shares of Preferred Shares which is at such time convertible into the number of shares of Common Stock which such Selling
Participant elects to sell; provided, however, that if the Third Party Purchaser objects to the delivery of Preferred Shares in lieu of Common Stock, such Selling Participant will convert such Preferred Shares into Common Stock and deliver Common
Stock. The Company agrees to make any such conversion concurrent with the actual transfer of such shares to the Third Party Purchaser. 

  
 - 4 -

 (e) The stock certificate or certificates, if any, that a Selling Participant delivers to
the Selling Stockholder pursuant to Section 2.3(d) above will be transferred to the Third Party Purchaser in consummation of the sale of the Shares pursuant to the terms and conditions specified in the Notice, and the Selling Stockholder will
concurrently therewith remit to such Selling Participant that portion of the sale proceeds to which such Selling Participant is entitled by reason of its participation in such sale. To the extent that any Third Party Purchaser, prohibits such
assignment or otherwise refuses to purchase shares or other securities from a Selling Participant exercising its rights of co-sale hereunder, the Selling Stockholder will not sell to such Third Party Purchaser any Shares unless and until,
simultaneously with such sale, (1) the Selling Stockholder will purchase such shares or other securities from such Selling Participant or (2) the Third Party Purchaser agrees to purchase shares or other securities from a Selling
Participant on the terms required by this Agreement. 
 2.4 No Effect on Rights. 

The exercise or non-exercise of the rights of any Preferred Holder hereunder to participate in one or more sales of Shares made by any
Selling Stockholder or to elect to purchase the Shares covered in a Notice from any Selling Stockholder will not adversely affect such Preferred Holder’s rights to participate in subsequent sales or purchases of Shares subject to Section 2
hereof. 
 2.5 Reoffers. 
 If the Preferred Holders do not elect to participate in the sale, or to purchase any of the Shares subject to the Notice, or to the extent the Preferred Holders or the Company elect not to participate in
the sale or purchase of all of the Shares subject to the Notice, the Selling Stockholder may, no later than sixty (60) days following delivery to the Preferred Holders of the Notice, enter into an agreement providing for the closing of the
transfer of the remaining Shares covered by the Notice within thirty (30) days of such agreement on the same terms and conditions as those described in the Notice. Any proposed transfer on terms and conditions more favorable than those
described in the Notice, as well as any subsequent proposed transfer of any of the remaining Shares by the Selling Stockholder, will again be subject to the co-sale, first refusal and other rights of the Preferred Holders set forth in this
Section 2 and will require compliance by the Selling Stockholder with the procedures described in this Section 2. 

2.6 Additional Stockholders. 
 The Company agrees that, prior to the issuance of any shares of capital stock of the Company to any person not a party to this Agreement, including upon exercise of stock options for the purchase of
Common Stock issued pursuant to the Company’s Amended 2004 Equity Compensation Plan, as amended (collectively, the “Plan”), the Company will cause such person to execute an Agreement to Join as a Party, in substantially the
form attached hereto as Exhibit A, and all references in this Agreement to “Stockholders” or “Stockholder” will include such 

  
 - 5 -

 
person so joining as a party. Nothing in this Section 2.6 will be construed to remove any limitations on the issuance of additional shares of capital stock by the Company contained in any
other agreement or document by which the Company is bound. The parties hereto agree that any such person or entity executing such Agreement to Join as a Party at the request of and with the consent of the Company will be deemed a
“Stockholder” under this Agreement and that no amendment to this Agreement need be executed by the parties hereto. Notwithstanding the foregoing, if any such person, after such issuance would not hold more than one percent (1%) of the
Company’s outstanding capital stock, on a fully-diluted, as-converted basis, such person need only (in lieu of the agreement described above in this Section 2.6) enter into a binding written undertaking to subject such shares to the
transfer restriction and drag along rights set forth in Sections 2.7 and 2.8 below. 
 2.7 Approval of the Board of
Directors. 
 Notwithstanding anything herein to the contrary, each Stockholder (except RMI in the events set forth in
Section 3.1 hereof) agrees not to sell or otherwise transfer any of such Stockholder’s Shares without the approval of the Board of Directors, which approval will only be withheld if it in good faith and reasonably determines that the
proposed transferee of the Shares is a competitor of the Company or is a party that is demonstrably hostile toward the Company or otherwise has interests that are detrimental to or inconsistent with those of the Company, or that the timing of the
proposed transfer of Shares would adversely affect a material pending transaction between the Company and another party. 
 2.8
Drag Along Rights. 
 In the event that (i) a majority of the members of the Board of Directors of the Company, and
(ii) the holders of at least a majority of voting power of the outstanding Preferred Shares (determined on an as converted to Common Stock basis and voting as a single class) approve an action which results in: (a) the sale, conveyance or
other disposition of all or substantially all of the assets of the Company or any subsidiary of Company (other than liens to secure loans approved by the Board of Directors of the Company); or (b) any transaction resulting in a Change in
Control (as defined in Section 6.4(b) below) (each a “Drag-Along Sale”), each Stockholder hereby agrees to (x) vote and/or sell all the shares of the capital stock of the Company held by it, him or her to effectuate the
sale, conveyance, or other disposition of all or substantially all of the assets or capital stock of the Company (or its subsidiary) or the merger or consolidation of the Company (or its subsidiary) with or into such other corporation or entity
acquiring, merging or consolidating with the Company and (y) use his, her or its best efforts to effect the closing of such transaction, including without limitation entering into all customary agreements and other documents as may be
reasonably required to close such transaction. 
 2.9 Limitation of Certain Obligations. 

Notwithstanding any other provision of this Agreement or any other agreement or document filed, executed and delivered in connection with
the Purchase Agreement, in connection with a Drag-Along Sale, (i) no Preferred Holder shall be required to make any representations or warranties other than that (A) such Preferred Holder owns its Preferred Shares free and clear of all
liens, security interests and encumbrances, (B) the obligations of such 

  
 - 6 -

 
Preferred Holder in connection with the proposed transaction have been duly authorized, if applicable, (C) the documents to be entered into by such Preferred Holder have been duly executed
by such Preferred Holder and delivered to the acquirer and are enforceable against such Preferred Holder in accordance with their respective terms and (D) neither the execution and delivery of documents to be entered into in connection with the
transaction, nor the performance of the Preferred Holder’s obligations thereunder, will cause a breach or violation of the terms of any agreement, law or judgment, order or decree of any court or governmental agency, (ii) no Preferred
Holder shall be liable for the inaccuracy of any representation or warranty made by any other Person in connection with the proposed Drag-Along Sale, other than the Company (except to the extent that funds may be paid out of an escrow established to
cover breach of representations, warranties and covenants of the Company as well as breach by any other Person of any identical representations, warranties or covenants provided by all Preferred Holders); (iii) the liability for
indemnification, if any, of such Preferred Holder in such proposed Drag-Along Sale is several and not joint with any other Person (except to the extent that funds may be paid out of an escrow established to cover breach of representations,
warranties and covenants of the Company as well as breach by any Person of any identical representations, warranties or covenants provided by all Preferred Holders), and is pro rata in proportion to the amount of consideration paid to such Preferred
Holder in connection with such proposed Drag-Along Sale; and (iv) any disbursements to the transferee of Shares from such escrow account shall be made on a pro rata basis. 
 SECTION 3. EXEMPT TRANSFERS. 
 3.1 Certain Transfers. 

Notwithstanding the foregoing, the provisions of Sections 2.1 through 2.5 hereof will not apply to (a) any pledge of Shares made
pursuant to a bona fide loan transaction that creates a mere security interest; (b) any transfer of Shares to a partner or member of, or a corporation, company, partnership, or other business entity which controls or is controlled by, or is
under common control with, a Stockholder (an “Affiliate”) and in the case of RMI, any transfer of Shares (i) to any third party so long as such Shares remain subject to an agreement to vote such shares in accordance with
RMI’s instructions, or (ii) to any of its Strategic Investors (as defined below) domiciled in (or controlled by a person domiciled in) countries of the Commonwealth of Independent States (CIS), including without limitation Armenia,
Azerbaijan, Belarus, Kazkhstan, Kyrgyzstan, Moldova, Russian Federation, Tajikistan, Uzbekistan as well as Turkmenistan, Ukraine and Georgia, who will vote such shares on its own behalf); (c) any transfer to the ancestors, descendants or spouse
of a Stockholder, or to trusts or family limited partnerships for the benefit of such persons including such Stockholder; or (d) any bona fide gift; provided, however, that, in any such case (i) the transferor will inform the Board of
Directors of such pledge, transfer or gift prior to effecting it; and (ii) the pledgee, transferee or donee will furnish the Company with a written agreement to be bound by and comply with all provisions of Section 2 hereof as well as the
terms of any other restrictive agreement to which such Shares are subject. Such transferred Shares will remain “Shares” hereunder, and such pledgee, transferee or donee will be treated as a “Stockholder” for
purposes of this Agreement. For the purposes of this Agreement, “Strategic Investor” means such investor that operates in the same industry as RMI or is in a joint venture or strategic alliance with RMI or its Affiliate(s).

  
 - 7 -

 3.2 Public Offering; Company Transfers. 

Notwithstanding the foregoing, the provisions of Section 2 hereof will not apply to and will terminate upon (a) the sale of any
Shares in a Qualified IPO (as defined in the Company’s Fifth Amended and Restated Certificate of Incorporation) or (b) the closing of the Company’s sale of all or substantially all of its assets or the acquisition of the Company by
another entity by means of a merger or consolidation resulting in the exchange of the outstanding shares of the Company’s capital stock for securities or consideration issued, or caused to be issued, by the acquiring entity or its subsidiary.

 SECTION 4. PROHIBITED TRANSFERS. 
 4.1 Put Option Right. In the event a Stockholder should sell any Shares in contravention of the co-sale rights under Section 2 of this Agreement (each, a “Prohibited Transfer”), the
Preferred Holders, in addition to such other remedies as may be available at law, in equity or hereunder, will have the put option provided below, and the Selling Stockholder will be bound by the applicable provisions of such option. 

4.2 Put Option. In the event of a Prohibited Transfer, each Preferred Holder will have the right to sell to the Selling
Stockholder the number of Shares equal to the number of shares such Preferred Holder would have been entitled to transfer to the purchaser had the Prohibited Transfer (under Section 2.3 hereof) been effected pursuant to and in compliance with
the terms and conditions of this Agreement. Such sale will be made on the following terms and conditions: 
 (a) the price per
share at which the shares are to be sold will be equal to the price per share paid by the purchaser in the Prohibited Transfer. The Selling Stockholder will also reimburse such Preferred Holder for any and all fees and expenses, including legal fees
and expenses, incurred pursuant to the exercise or the attempted exercise of the Preferred Holder’s rights under Section 2; 
 (b) within ninety (90) days after the later of the dates on which a Preferred Holder (i) received notice of the Prohibited Transfer or (ii) otherwise became aware of the Prohibited
Transfer, such Preferred Holder will, if exercising the option created hereby, have available for delivery to the Selling Stockholder the certificate or certificates representing shares to be sold, each certificate to be properly endorsed for
transfer or accompanied by an executed stock power to effect such transfer; 
 (c) the Selling Stockholder will, upon receipt of
notice of the availability of the certificate or certificates for the Shares to be sold by a Preferred Holder, pursuant to this Section 4.2, pay the aggregate purchase price therefor and the amount of reimbursable fees and expenses, as
specified in Section 4.2(a) hereof, in cash or by other means acceptable to the Preferred Holder, and the Preferred Holder will deliver to the Selling Stockholder the certificate or certificates for the Shares to be sold pursuant to this
Section 4.2; and 
 Notwithstanding the foregoing, any attempt by a Selling Stockholder to transfer Shares in violation of
Section 2 hereof will be voidable at the option of a majority in interest of the Preferred Holders, and the Company agrees it will not effect such a transfer nor will it treat any alleged transferee as the holder of such Shares without the
prior written consent of a majority in interest of the Preferred Holders 

  
 - 8 -

 SECTION 5. LEGEND. 
 5.1 Legend. 
 Each certificate representing the Shares or shares issued to
any Founder, Common Stockholder or Preferred Holder and each certificate representing the Shares or shares issued to any person in connection with a transfer pursuant to Sections 2 or 3 hereof will be endorsed with the following legend: 

“THE SALE, PLEDGE, HYPOTHECATION OR TRANSFER OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE IS SUBJECT TO THE TERMS AND CONDITIONS
OF A CERTAIN THIRD AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT, AS AMENDED, BY AND AMONG THE STOCKHOLDER, THE CORPORATION AND CERTAIN HOLDERS OF STOCK OF THE CORPORATION. COPIES OF SUCH AGREEMENT MAY BE OBTAINED UPON WRITTEN REQUEST TO THE
SECRETARY OF THE CORPORATION.” 
 5.2 Stop Orders. 

Each Stockholder agrees that the Company may instruct its transfer agent to impose transfer restrictions on the shares represented by
certificates bearing the legend referred to in Section 5.1 above to enforce the provisions of this Agreement and the Company agrees to do so promptly. The legend will be removed upon termination of this Agreement. 

SECTION 6. COVENANTS OF THE COMPANY AND STOCKHOLDERS. 
 6.1 Basic Information. 
 The Company hereby covenants and agrees that it
will furnish the following reports to the Board of Directors, any Preferred Holder for so long as such Preferred Holder owns at least 5% of the issued and outstanding Shares on a fully diluted basis (as adjusted for stock splits, dividends and
combinations) (each such Preferred Holder, a “Major Holder”): 
 (a) as soon as practicable after the end of
each fiscal year of the Company, and in any event within one hundred twenty (120) days thereafter, a consolidated balance sheet of the Company and its subsidiaries, if any, as of the end of such fiscal year, and consolidated statements of
income, and cash flows, as well as status reports, forecasts and sales results, of the Company and its subsidiaries, if any, for such year, prepared in accordance with generally accepted accounting principles consistently applied and setting forth
in each case in comparative form the figures for the previous fiscal year, all in reasonable detail and audited by independent public accountants mutually agreed upon by the Company and the holders of a majority of the Preferred Shares and a Company
sales results report and comparison to the Company’s operating plan for such year. 

  
 - 9 -

 (b) as soon as practicable after the end of the first, second, and third quarterly
accounting periods in each fiscal year of the Company, and in any event within thirty (30) days thereafter, an unaudited, consolidated balance sheet of the Company and its subsidiaries, if any, as of the end of each such quarterly period, and
unaudited, consolidated statements of income and cash flows, as well as status reports, forecasts and sales reports, of the Company and its subsidiaries, if any, for such period and for the current fiscal year to date, setting forth in comparative
form the figures for the corresponding periods of the previous fiscal year and to the Company’s operating plan then in effect and approved by its Board of Directors, subject to changes resulting from normal year-end audit adjustments, all in
reasonable detail and certified by the principal financial or accounting officer of the Company, except that such financial statements need not contain the notes required by generally accepted accounting principles. 

(c) copies of any documents (promptly after receipt of such documents by the Company) relating to material litigation and governmental
correspondence and breaches of material agreements. On an annual basis, the Company will provide a list, to the best knowledge of management, of any outstanding litigation or governmental investigations. 

6.2 Additional Information and Rights. 
 (a) The Company hereby covenants and agrees that it will permit each Major Holder (or its representative) upon request, to visit and inspect any of the properties of the Company, including its books of
account and other records (and make copies thereof and take extracts therefrom), and to discuss its affairs, finances and accounts with the Company’s officers and its independent public accountants, all at such reasonable times and as often as
any such person may reasonably request. In addition, the Company hereby covenants and agrees that it will automatically deliver the following reports to each such Major Holder and each member of the Company’s Board of Directors: 

(i) as soon as practicable after the end of each month and in any event within thirty (30) days thereafter, an unaudited,
consolidated balance sheet of the Company and its subsidiaries, if any, as at the end of such month and unaudited, consolidated statements of income and cash flows, as well as status reports, forecasts and sales reports, of the Company and its
subsidiaries, if any, for each month and for the current fiscal year of the Company to date, all subject to normal year-end audit adjustments, certified by the principal financial or accounting officer of the Company, together with a comparison of
such statements to the corresponding periods of the prior fiscal year and to the Company’s operating plan then in effect and approved by its Board of Directors; 
 (ii) quarterly updates on the scientific, clinical and business development activity of the Company; 
 (iii) annually (and in any event no later than ten (10) days after adoption by the Board of Directors of the Company) the financial plan of the Company, in such manner and form as approved by the
Board of Directors of the Company, which financial plan will include at least a projection of income and a projected cash flow statement for each fiscal quarter in such fiscal year and a projected balance sheet as of the end of each fiscal quarter
in such fiscal year. Any material changes in such financial plan will be delivered to each Preferred 

  
 - 10 -

 
Holder that has a right to receive such plan as promptly as practicable after such changes have been approved by the Board of Directors of the Company. In addition, the Company will prepare and
deliver to each such Major Holder the annual business and operating plan and annual budget of the Company with financial projections for approval by the Board of Directors no later than thirty (30) days prior to the beginning of each fiscal
year of the Company. 
 (b) The provisions of Section 6.1 and this Section 6.2 will not be in limitation of any rights
which a Preferred Holder may have with respect to the books and records of the Company and its subsidiaries, if any, or to inspect their properties or discuss their affairs, finances and accounts, under the applicable law. 

(c) Notwithstanding the foregoing, the Company’s obligations under Sections 6.1 and 6.2 hereof will not apply to and will terminate
upon the effective date of a registration statement covering any initial public offering of the Company’s capital stock that is filed by the Company with the Securities and Exchange Commission under the Securities Act of 1933, as amended

 6.3 Proprietary Information, Assignment of Inventions, Confidentiality and Non-Compete Agreements. 

The Company hereby covenants and agrees that it will cause each Founder, officer, manager, and key employee of the Company or any other
person now or hereafter employed by it or any subsidiary with access to confidential information of the Company to enter into a proprietary information, assignment of inventions, confidentiality agreement and non-compete and non-solicitation
agreements prior to employment (or the date hereof, with respect to current employees) reasonably acceptable to the Company and the Preferred Holders (the “Proprietary Information Agreement”). The Proprietary Information Agreement
will contain among other things, provisions obligating each such Founder, officer, manager, and key employee of the Company to assign all of the intellectual developed by such persons (including, without limitation, all patents, copyrights, and
trademarks) to the Company and will restrict each such Founder, officer, manager, and key employee of the Company from competing with the Company. The Company hereby covenants and agrees that it will cause, or will have caused, each consultant now
or hereafter engaged by it to enter into an agreement containing terms substantially similar terms to those currently governing intellectual property generated by consultants. 
 6.4 Employee and Other Stock Arrangements. 
 (a) The Company hereby
covenants and agrees that it will not, without the approval of a majority of the Board of Directors, including the approval of a majority of the directors elected by the Preferred Holders, issue any of its capital stock, or grant an option or rights
to subscribe for, purchase or acquire any of its capital stock, to any employee, consultant, officer or director of the Company or a subsidiary or pursuant to conversion rights set forth in the Fourth Amended and Restated Certificate of
Incorporation, as amended; provided, however, that such grants of options pursuant to the Plan may be granted without the approval of the Board of 

  
 - 11 -

 
Directors if approved in compliance with the Plan. Each acquisition of any shares of capital stock of the Company or any option or right to acquire any shares of capital stock of the Company by
an employee, officer or director of the Company, except for the issuance of shares of Common Stock to individuals or entities other than the Founders pursuant to the exercise of options granted under the Plan, will be conditioned upon the execution
and delivery by the Company and such employee, officer or director of an agreement substantially in a form approved by the Board of Directors of the Company. 
 (b) The Company hereby covenants and agrees that the shares of Common Stock reserved for issuance upon the exercise of stock options granted after the date hereof will be subject to vesting provisions.
The Company hereby covenants and agrees that such vesting provisions will provide that such stock, stock options or rights vest not more than twenty-five percent (25%) on the first anniversary date of the commencement of the employment of such
holder and, subject to continued employment of such holder by the Company, not more than 2.083% on the last day of each full month thereafter. The Company hereby covenants and agrees that such vesting provisions will provide that (i) such
stock, stock options or rights shall not vest upon an initial public offering of the Company’s securities and (ii) upon a Change of Control of the Company (as defined in the below) any accelerated vesting will be subject to the discretion
of the Board of Directors of the Company. Notwithstanding the foregoing, such vesting schedule may be altered with respect to individual option grants as approved by the Board of Directors or committee thereof, provided that such approval includes
the affirmative vote of a majority of the Directors elected by the Preferred Holders. For purposes of this Agreement, “Change of Control” shall mean (a) merger or consolidation of the Company with or into another entity in
which the shareholders of the Company immediately prior to such merger or consolidation own less than 50% of the voting securities of the surviving entity, (b) any other transaction or series of transactions as a result of which the
shareholders of the Company immediately prior to such transaction or series of transactions own less than 50% of the voting securities of the Company or other surviving entity following such transaction (other than the sale of equity securities by
the Company in a capital raising transaction) or (c) the sale or license of all or substantially all of the assets of the Company. 
 6.5 Transactions with Affiliates. 
 The Company hereby covenants and agrees
that it will not, without the approval of a majority of the disinterested members of the Company’s Board of Directors, including the approval of directors elected by the Preferred Holders (except to the extent such directors are not
disinterested), engage in any material transactions, including any loans, leases, contracts or other transactions or approve stock purchases with or by any director, officer, key employee, or Stockholder of the Company, or any member of any such
person’s immediate family, including the parents, spouse, children and other relatives of any such person, other than arms’ length transactions in the ordinary course of the Company’s business or its corporate affiliates, as otherwise
permitted under the Plan or as contemplated by the Purchase Agreement. 

  
 - 12 -

 6.6 Protection of Company Intellectual Property Rights and Inventions. 

The Company hereby covenants and agrees that it will take reasonable steps to ensure protection of its intellectual property, including
but not limited to, the pursuit of all appropriate patents, copyrights, trademarks, and service marks, of all technology developed on its behalf by employees, consultants, independent contractors and others. The Company hereby covenants and agrees
that it will utilize appropriate agreements with its employees, consultants, independent contractors and agents concerning the protection of its intellectual property. 
 6.7 Company Covenants. 
 (a) The Company hereby covenants and agrees that
Directors will be insured by the Company, through the purchase of director’s liability insurance, in coverage amounts and types reasonable for similarly situated businesses, and will be indemnified by the Company to the fullest extent provided
under applicable law, and shall execute the Company’s customary directors’ indemnification agreement with each Director. 
 (b) The Company hereby covenants and agrees that all reasonable, documented expenses incurred by a director of the Company in attending Board meetings or meetings of Board committees of which such
director is a member and performing Company duties will be borne by the Company. 
 (c) The Company hereby covenants and agrees
that a compensation committee of the Board of Directors, consisting of duly and validly elected directors of the Company, none of whom are employees of the Company, will approve all compensation packages (including options and bonuses) for key
employees of the Company, including, without limitation, the President and Chief Executive Officer of the Company. Any and all committees of the Board of Directors (including, without limitation, such compensation committee), will include at least
two (2) members elected by the holders of the Preferred Shares. 
 (d) The Company hereby covenants and agrees that
meetings of the Board of Directors will be held at least four (4) times per calendar year until such time as the Board of Directors, including all members elected by the holders of the Preferred Shares, determines otherwise. Special meetings
may be called by the Board of Directors at such time as it deems necessary pursuant to the Bylaws. 
 (e) Any non-employee
member of the Board of Directors shall be compensated equally but for the Chairman of the Board of Directors, who, at the discretion of the stockholders, may receive a premium for his services on the Board of Directors pursuant to a
stockholders’ approved director compensation program. 
 6.8 Voting. 

(a) Each Stockholder agrees to vote, or cause to be voted, all Shares owned by such Stockholder or over which such Stockholder has voting
control, from time to time and at all times, in whatever manner as shall be necessary to ensure that at each annual or special meeting of stockholders at which an election of directors is held or pursuant to any written consent of the stockholders,
the Board of Directors is comprised of two Stockholder Directors, the Series E Director, the Series D Preferred Director, the Series C Preferred Director, the Series B Preferred Director and the Series A Preferred Director (each as defined the Fifth
Amended & Restated Certificate of Incorporation), each as designated respectively by those Preferred Holders entitled to nominate directors pursuant to the Fifth Amended and Restated Certificate of Incorporation. No Stockholder shall vote
to remove any director designated by a holder of any series of Preferred Shares unless instructed to do so by the holder of shares of such series of Preferred Shares entitled to designate such director. 

  
 - 13 -

 (b) In the absence of any designation from Stockholders with the right to designate a
director, the director previously designated by such Stockholders then serving shall be reelected if still eligible to serve as provided herein. 
 6.9 Board Observer. 
 (a) As long as RMI owns not less than 500,000 shares
of Series E Preferred Stock (or an equivalent amount of Common Stock issued upon conversion thereof), which number is subject to appropriate adjustment for all stock splits, dividends, combinations, recapitalizations and the like, the Company shall
invite a representative of RMI to attend all meetings of its Board of Directors in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents, and other materials that it provides to
its directors; provided, however, that such representative shall agree to hold in confidence and trust and to act in a fiduciary manner with respect to all information so provided; and provided further, that the Company reserves the right to
withhold any information and to exclude such representative from any meeting or portion thereof if access to such information or attendance at such meeting could adversely affect the attorney-client privilege between the Company and its counsel or
result in disclosure of trade secrets or a conflict of interest, or if such Investor or its representative is a competitor of the Company. 
 (b) As long as Baxter Healthcare Corporation (“Baxter”) owns not less than 500,000 shares of Series E Preferred Stock (or an equivalent amount of Common Stock issued upon conversion
thereof), which number is subject to appropriate adjustment for all stock splits, dividends, combinations, recapitalizations and the like, the Company shall invite a representative of Baxter to attend all meetings of its Board of Directors in a
nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents, and other materials that it provides to its directors; provided, however, that such representative shall agree to hold in
confidence and trust and to act in a fiduciary manner with respect to all information so provided; and provided further, that the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion
thereof if access to such information or attendance at such meeting could adversely affect the attorney-client privilege between the Company and its counsel or result in disclosure of trade secrets or a conflict of interest, or if such Investor or
its representative is a competitor of the Company. 
 6.10 Public Relations. 

The Company covenants and agrees to give reasonable prior written notice to a representative of Aurora Ventures V, LP, Domain Partners
VI, L.P., Quaker Bioventures, L.P. and BioDiscovery 3 FCPR of all press releases to be issued by the Company, including, without limitation, any press release to be issued in connection with the transactions contemplated by the Purchase Agreement.
So long as each of Aurora Ventures V, LP, Domain Partners VI, L.P., Quaker Bioventures, L.P., and BioDiscovery 3 FCPR owns at least five percent (5%) of the total issued and outstanding Shares of the Company on a fully-diluted basis, all press
releases of the 

  
 - 14 -

 
Company will include language approved by both the Company and such entity stating that the Company is a portfolio company of such entity. The Company agrees that each Major Holder shall have the
right to issue a press release or make a public statement or announcement disclosing such Investor’s investment in the Company or otherwise use the Company’s name, provided, however, that such Investor submit such proposed release or
announcement to the Company for review prior to issuing such release or making such announcement and such announcement is reasonably acceptable (both in timing and content) to the Company. 
 SECTION 7. MISCELLANEOUS. 
 7.1 Confidentiality. 

Anything in this Agreement to the contrary notwithstanding, no Preferred Holder solely by reason of this Agreement shall have access to
any trade secrets or classified information of the Company. Each Preferred Holder acknowledges that the information received by it pursuant to this Agreement may be confidential and for its use only, and it will not use such confidential information
in violation of applicable law or otherwise or reproduce, disclose or disseminate such information to any other person (other than its employees or agents having a need to know the contents of such information, and its attorneys), except in
connection with the exercise of rights under this Agreement, unless the Company has made such information available to the public generally. 
 7.2 Conditions to Exercise of Rights. 
 Exercise of the rights set forth in
this Agreement will be subject to and conditioned upon compliance with applicable laws. 
 7.3 Governing Law. 

This Agreement shall be governed by and construed under the laws of the State of Delaware without regard to conflicts of laws principles,
and shall be binding upon the parties hereto in the United States and worldwide. All disputes with respect to this Agreement shall be brought and heard either in the New York state courts located in New York County, New York, or the federal district
courts of New York. The parties to this Agreement each consent to the in personam jurisdiction and venue of such courts. The parties agree that service of process upon them in any such action may be made if delivered in person, by courier
service, by telegram, by telefacsimile or by first class mail, and shall be deemed effectively given upon receipt. 
 7.4
Amendment. 
 Any provision of this Agreement may be amended and the observance thereof may be waived (either generally
or in a particular instance and either retroactively or prospectively), only by the written consent of the Company, the holders of a majority or more of the Common Stock and the holders of at least a majority of the Preferred Shares voting on an as
converted basis; provided, however, that Sections 2.7, 3.1 and 6.9 may not be amended or waived with respect to RMI’s rights without the written consent of RMI as long as RMI owns not less than 500,000 shares of Series E Preferred
Stock (or an equivalent amount of Common Stock issued upon conversion thereof), and any such amendment or waiver will be binding on each Stockholder and such Stockholder’s successors, heirs and assigns, but in no event will the obligations of
any Stockholder hereunder be materially increased, except upon the written consent of such Stockholder. 

  
 - 15 -

 7.5 Assignment of Rights. 

This Agreement and the rights and obligations of the parties hereunder will inure to the benefit of, and be binding upon, the
parties’ respective successors, assigns and legal representatives. The rights of the Stockholders hereunder are only assignable (a) by each of such Stockholders to any other Stockholder or (b) to an assignee or transferee who acquires
all of the Shares purchased by a Stockholder and such assignee or transferee will then become a party to this Agreement. 
 7.6
Specific Performance. 
 In addition to any and all other remedies that may be available at law in the event of any
breach of this Agreement, each Investor shall be entitled to specific performance of the agreements and obligations of the Company and the Stockholders hereunder and to such other injunction or other equitable relief as may be granted by a court of
competent jurisdiction. 
 7.7 Termination. 
 The rights and covenants established in this Agreement will terminate upon the earlier of (a) the conversion of the Preferred Shares pursuant to Article IV.D.4(b) of the Company’s Fifth Amended
and Restated Certificate of Incorporation, or (b) a Change of Control. 
 7.8 Ownership. 

Each Founder represents and warrants that such Founder is the sole legal and beneficial owner of the shares of stock subject to this
Agreement and that no other person has any interest in such shares. 
 7.9 Notices. 

All notices and other communications required or permitted hereunder will be in writing and will be sent by facsimile or email or
delivered personally by hand or nationally recognized courier addressed (a) if to a Stockholder, to the address, facsimile number or email address indicated on the signature pages of this Agreement, or at such other address, facsimile number or
email address as such holder or permitted assignee will have furnished to the Company in writing, or (b) if to the Company, to the address, facsimile number or email address indicated on the signature pages of this Agreement, or at such other
address, facsimile number or email address as the Company will have furnished to each Stockholder in writing. All such notices and other written communications will be effective on the date confirmed facsimile or email receipt or delivery.

  
 - 16 -

 7.10 Severability. 

In the event one or more of the provisions of this Agreement should, for any reason, be held to be invalid, illegal or unenforceable in
any respect, such invalidity, illegality or unenforceability will not affect any other provisions of this Agreement, and this Agreement will be construed as if such invalid, illegal or unenforceable provision had never been contained herein.

 7.11 Attorney Fees. 
 In the event that any dispute among the parties to this Agreement should result in litigation, the prevailing party in such dispute will be entitled to recover from the losing party all reasonable,
documented fees, costs and expenses of enforcing any right of such prevailing party under or with respect to this Agreement, including without limitation, such reasonable fees and expenses of attorneys and accountants, which will include, without
limitation, all reasonable fees, costs and expenses of appeals. 
 7.12 Counterparts. 

This Agreement may be executed in two or more counterpart signature pages (including facsimile counterpart signature pages), each of
which will be deemed an original, but all of which, when taken together, will constitute one and the same instrument. 
 7.13
Entire Agreement. 
 This Agreement constitutes the entire agreement between the parties relative to the specific subject
matter hereof. Any previous agreement among the parties hereto (whether oral or written) relative to the specific subject matter hereof is expressly superseded by this Agreement. 

[Remainder of page left intentionally blank] 
 [Signature pages to follow] 

  
 - 17 -

 [Signature pages to Regado Biosciences, Inc. Investors’ Rights Agreement]

 IN WITNESS WHEREOF, the foregoing Third Amended and Restated Investors’ Rights Agreement is hereby executed by the
undersigned as of the date first above written. 
 THE COMPANY: 

 

			
	REGADO BIOSCIENCES, INC.
		
	By:	 	/s/ David J. Mazzo
	Name:	 	David J. Mazzo, Ph.D.
	Title:	 	President and Chief Executive Officer

 [Signature Pages to Regado Biosciences, Inc. Investors’ Rights Agreement]

 THE PREFERRED HOLDERS: 
  

			
	RMI INVESTMENTS, S.á r.l.
		
	By:	 	Vladimir Gurdus
	Its Director
		
	By:	 	/s/ Vladimir Gurdus

 [Signature Pages to Regado Biosciences, Inc. Investors’ Rights Agreement]

  

			
	BAXTER HEALTHCARE CORPORATION
		
	By:	 	/s/ Norbert Riedel

 [Signature Pages to Regado Biosciences, Inc. Investors’ Rights Agreement]

  

			
	 DOMAIN PARTNERS VI, L.P.
  

By: One Palmer Square Associates VI, L.L.C.
 Its
General Partner

		
	By:	 	/s/ Kathleen Schoemaker

 [Signature Pages to Regado Biosciences, Inc. Investors’ Rights Agreement]

  

			
	 DP VI ASSOCIATES, L.P.
  

By: One Palmer Square Associates VI, L.L.C.
 Its
General Partner

		
	By:	 	/s/ Kathleen Schoemaker

 [Signature Pages to Regado Biosciences, Inc. Investors’ Rights Agreement]

  

			
	 QUAKER BIOVENTURES, L.P.
  

By: Quaker Bioventures Capital, L.P.
 Its General
Partner

		
	By:	 	Quaker Bioventures Capital, LLC
	Its General Partner

  

			
	By:	 	/s/ Sherrill Neff

 [Signature Pages to Regado Biosciences, Inc. Investors’ Rights Agreement]

  

			
	 AURORA VENTURES V, LLC
  

By: A.V. Management V, L.L.C,
 Its Managing
Member

		
	By:	 	/s/ B. Jefferson Clark

  

			
	 AURORA VENTURES IV, LLC
  

By: A.V. Management IV, L.L.C,
 Its Managing
Member

		
	By:	 	/s/ B. Jefferson Clark

 [Signature Pages to Regado Biosciences, Inc. Investors’ Rights Agreement]

  

			
		 	/s/ Robert Kierlin
		 	Robert Kierlin, Individually

  

 [Signature Pages to Regado Biosciences, Inc. Investors’ Rights Agreement]

  

			
	 CAXTON ADVANTAGE LIFE SCIENCES FUND, L.P.

 
 By: Caxton Advantage Venture Partners, L.P.

Its General Partner
  
 By: Advantage Life Sciences Partners, LLC
 Its Managing General Partner

		
	By:	 	/s/ Eric Roberts

 [Signature Pages to Regado Biosciences, Inc. Investors’ Rights Agreement]

  

			
	 BIODISCOVERY 3 FCPR
  

By: EDMOND DE ROTHSCHILD INVESTMENT PARTNERS, its management company

		
	By:	 	/s/ Raphael Wisniewski

 [Signature Pages to Regado Biosciences, Inc. Investors’ Rights Agreement]

 THE FOUNDERS: 
  

			
		 	/s/ Christoper P. Rusconi

 SCHEDULE A 

Founders 
 Eli Gilboa 
 Doug Gooding 

Christopher P. Rusconi 
 Bruce Sullenger 
 Common Stockholders 

Archemix Corporation 
 Aurora Ventures IV, LLC 
 Robert Bonczak 

Doug Brooks 

Domain Partners IV, L.P. 
 DPV IV Associates, L.P. 
 Duke University 

Eli Gilboa 
 Doug
Gooding 
 Robert Kierlan 
 Casey and Jenny Kopczynski 
 Doug Kornbrust 

Jeffrey Lipton 

Matton Venture Partners V 
 MedInnova Partners, Inc. 
 Claude T. Moorman, III, M.D. 

Quaker Bioventures, L.P. 
 Christopher Rusconi 
 Susan Srivatsa 

Bruce Sullenger 

Ross Tonkens 

University License Equity Holdings, Inc. 
 Lynn Wilson 
 Fran Wincot 

University Medical Devices, Inc. 
 Series A Investors 
 Aurora Ventures IV, LLC 

Robert Kierlin 

 Series B Investors 

Domain Partners VI, L.P. 
 DP VI Associates, L.P. 
 Quaker Bioventures, L.P. 

Aurora Ventures IV, LLC 
 Robert Kierlin 
 Robert M. Bonczek 

Jeffrey M. Lipton 

Matton Venture Partners V 
 Claude T. Moorman, III, M.D. 
 Series C Investors 

Domain Partners VI, L.P. 
 DP VI Associates, L.P. 
 Quaker Bioventures, L.P. 

Aurora Ventures IV, LLC 
 Robert Kierlin 
 Caxton Advantage Life Sciences Fund, L.P. 

Robert M. Bonczek 

Jeffrey M. Lipton 

Matton Venture Partners V 
 Claude T. Moorman, III, M.D. 
 Series D Investors 

Aurora Ventures V, LLC 
 Robert Kierlin 
 Domain Partners VI, L.P. 

DP VI Associates, L.P. 
 Quaker BioVentures, L.P. 
 Caxton Advantage Life Sciences Fund, L.P. 

BioDiscovery 3 FCPR 

Christopher E. Courts 
 Series E Investors 
 Domain Partners VI, L.P. 

DP VI Associates, L.P. 
 Quaker Bioventures, L.P. 

 Aurora Ventures V, LP 
 Robert Kierlin 
 Caxton Advantage Life Sciences Fund, L.P. 

BioDiscovery 3 FCPR 

RMI Investments, S.Á.R.L. 
 Baxter Healthcare Corporation 

 EXHIBIT A 

On file with CompanyEX-4.3

 Exhibit 4.3 
 REGADO BIOSCIENCES, INC. 
 THIRD AMENDED AND RESTATED REGISTRATION RIGHTS
AGREEMENT 
 This THIRD AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT (the “Agreement”) is made as of
the 18th day of December, 2012, by and among Regado Biosciences, Inc., a Delaware corporation (the “Company”), and the persons identified as “Series A Investors,” “Series B Investors,”
“Series C Investors,” “Series D Investors” and “Series E Investors” on Schedule A attached hereto (collectively, the “Investors”) amending and restating the Second
Amended and Restated Registration Rights Agreement, made as of December 18, 2009, by certain of the Investors named in the schedules thereto (the “Second Amended and Restated Registration Rights Agreement”). 

RECITALS: 

WHEREAS, the Company, the Series A Investors, the Series B Investors, the Series C Investors and Series D Investors previously entered
into the Second Amended and Restated Registration Rights Agreement; and 
 WHEREAS, the Company, the Series A Investors, the
Series B Investors, the Series C Investors and Series D Investors wish to amend and restate the Second Amended and Restated Registration Rights Agreement; and 
 WHEREAS, each of the Series E Investors is a party to that certain Series E Preferred Stock Purchase Agreement (the “Purchase Agreement”), dated the date hereof, pursuant to which they
are acquiring shares of the Company’s Series E Preferred Stock. Certain of the Company’s and the Series E Investors’ obligations under the Purchase Agreement are conditioned upon the execution and delivery by the Investors and the
Company of this Agreement. 
 NOW, THEREFORE, in consideration of the mutual promises and covenants set forth in this Agreement,
and intending to be legally bound, the parties agree as follows: 
 SECTION 1. RESTRICTIONS ON TRANSFERABILITY OF SECURITIES; REGISTRATION
RIGHTS. 
 1.1 Certain Definitions. 
 As used in this Agreement, the following terms will have the meanings set forth below: 
 (a) “Closing” will mean the date of the initial sale of shares of the Series E Preferred. 
 (b) “Commission” will mean the Securities and Exchange Commission or any other federal agency at the time administering the Securities Act. 

 (c) “Exchange Act” will mean the Securities Exchange Act of 1934, as
amended, or any similar successor federal statute and the rules and regulations thereunder, all as the same will be in effect from time to time. 
 (d) “Holder” or “Holders” will mean an Investor or Investors who hold(s) Registrable Securities and any holder of Registrable Securities to whom the registration rights
conferred by this Agreement have been transferred in compliance with Section 1.2 and Section 1.13 hereof. 
 (e)
“Initiating Holders” will mean any Holder or Holders of Registrable Securities who in the aggregate hold(s) more than fifty percent (50%) in interest of the Registrable Securities. 

(f) “Investor” will mean each person named on Schedule A hereto. 

(g) “Other Stockholders” will mean persons other than Holders who, by virtue of agreements with the Company, are
entitled to include their securities in certain registrations hereunder. 
 (h) “Preferred Shares” will mean
the Company’s Series A Preferred, the Company’s Series B Preferred, the Company’s Series C Preferred, the Company’s Series D Preferred and the Company’s Series E Preferred. 

(i) “Registrable Securities” will mean (i) shares of Common Stock issued or issuable pursuant to the conversion of
the Preferred Shares, and (ii) any Common Stock issued as a dividend or other distribution with respect to or in exchange for or in replacement or conversion of the shares referenced in (i) above; provided, however, that Registrable
Securities will not include any shares of Common Stock which have previously been registered or which have been sold to the public either pursuant to a registration statement or an exemption from registration under the Securities Act (including Rule
144), which have been sold in a private transaction in which the transferor’s rights under this Agreement are not assigned or which may be sold by an Investor in a three (3) month period in an open market transaction pursuant to Rule 144.

 (j) The terms “register,” “registered” and “registration” will refer to a
registration effected by preparing and filing a registration statement in compliance with the Securities Act and applicable rules and regulations thereunder, and the declaration or ordering of the effectiveness of such registration statement.

 (k) “Registration Expenses” will mean all expenses incurred in effecting any registration pursuant to this
Agreement, including, without limitation, all registration, qualification, and filing fees, printing expenses, escrow fees, fees and disbursements of counsel for the Company, fees and expenses of one (1) counsel for the Holders, blue sky fees
and expenses, and expenses of any regular or special audits incident to or required by any such registration, but will not include Selling Expenses. 
 (l) “Restricted Securities” will mean any Registrable Securities required to bear the legend set forth in Section 1.2(c) hereof. 

  
 -2-

 (m) “Rule 144” will mean Rule 144 as promulgated by the Commission under
the Securities Act, as such Rule may be amended from time to time, or any similar successor rule that may be promulgated by the Commission. 
 (n) “Rule 145” will mean Rule 145 as promulgated by the Commission under the Securities Act, as such Rule may be amended from time to time, or any similar successor rule that may be
promulgated by the Commission. 
 (o) “Second Closing Date” will mean the date of the Second Closing (as
defined in the Purchase Agreement), which shall take place on or before June 30, 2013, upon such date determined by the Board of Directors of the Company, who shall determine the Second Closing Date no later than June 15, 2013. 

(p) “Securities Act” will mean the Securities Act of 1933, as amended, or any similar successor federal statute and the
rules and regulations thereunder, all as the same will be in effect from time to time. 
 (q) “Selling
Expenses” will mean all underwriting discounts, selling commissions and stock transfer taxes applicable to the sale of Registrable Securities. 
 (r) “Series A Preferred” will mean the Company’s Series A Preferred Stock, $0.001 par value per share. 
 (s) “Series B Preferred” will mean the Company’s Series B Preferred Stock, $0.001 par value per share. 
 (t) “Series C Preferred” will mean the Company’s Series C Preferred Stock, $0.001 par value per share. 
 (u) “Series D Preferred” will mean the Company’s Series D Preferred Stock, $0.001 par value per share. 
 (v) “Series E Preferred” will mean the Company’s Series E Preferred Stock, $0.001 par value per share. 
 1.2 Restrictions on Transfer. 
 (a) Except as provided in the Third Amended
and Restated Investors’ Rights Agreement dated as of the date hereof, each Holder agrees not to make any disposition of all or any portion of the Registrable Securities unless and until either: 

(i) there is then in effect a registration statement under the Securities Act covering such proposed disposition and such disposition is
made in accordance with such registration statement; or 

  
 -3-

 (ii) the transferee has agreed in writing for the benefit of the Company to be bound by
this Section 1.2 and (A) such Holder will have notified the Company of the proposed disposition and will have furnished the Company with a detailed statement of the circumstances surrounding the proposed disposition, and (B) if
reasonably requested by the Company, such Holder will have furnished the Company with an opinion of counsel, reasonably satisfactory to the Company, that such disposition will not require registration of such shares under the Securities Act. It is
agreed that the Company will not require opinions of counsel for transactions made pursuant to Rule 144 except in unusual circumstances. 
 (b) Notwithstanding the provisions of Sections 1.2(a)(i) and (ii) above, no such registration statement or opinion of counsel will be necessary for a transfer involving a sale by a Holder
(A) which is a partnership, to its partners or retired partners in accordance with their interests in the partnership; (B) which is a corporation, to its shareholders in accordance with their interest in the corporation; (C) which is
a limited liability company, to its members or former members in accordance with their interest in the limited liability company; or (D) to the Holder’s immediate family member or a trust for the benefit of an individual Holder; provided
that, in each case, a condition precedent to any such transfer is that the transferee agrees to be subject to the terms of this Section 1.2 to the same extent as if such transferee were an original Holder hereunder. 

(c) Each certificate representing Registrable Securities will (unless otherwise permitted by the provisions of this Agreement) be stamped
or otherwise imprinted with a legend substantially similar to the following (in addition to any legend required under applicable state securities laws or the Company’s charter documents): 

THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND MAY NOT BE SOLD OR
TRANSFERRED, ASSIGNED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER SUCH ACT OR UNLESS THE COMPANY HAS RECEIVED AN OPINION OF COUNSEL OR OTHER EVIDENCE, SATISFACTORY TO THE COMPANY AND ITS COUNSEL, THAT SUCH REGISTRATION IS NOT
REQUIRED. 
 (d) The Company will be obligated to reissue promptly unlegended certificates at the request of any Holder thereof
if the Holder will have obtained an opinion of counsel at such Holder’s expense (which counsel may be counsel to the Company) reasonably acceptable to the Company to the effect that the securities proposed to be disposed of may lawfully be so
disposed of without registration, qualification or legend. 
 (e) Any legend endorsed on an instrument pursuant to applicable
state securities laws and the stop-transfer instructions with respect to such securities shall be removed upon receipt by the Company of an order of the appropriate blue sky authority authorizing such removal. 

  
 -4-

 1.3 Demand Registration. 

(a) If the Company will receive from the Initiating Holders at any time after the earlier of (i) the third anniversary of the Second
Closing Date or (ii) six (6) months after the effective date of the first registration statement filed by the Company covering an underwritten offering of any of its securities to the general public, a written request that the Company
effect any registration with respect to Registrable Securities held by such Initiating Holders such that the aggregate offering price to the public for the Registrable Securities offered would not be less than Seventy-Five Million Dollars
($75,000,000.00), the Company will: 
 (i) promptly give written notice of the proposed registration to all other Holders; and

 (ii) subject to Section 1.3(b), as soon as practicable, use its best efforts to effect such registration within ninety
(90) days of the date of such notice in Section 1.3(a)(i) above (including, without limitation, filing post-effective amendments, appropriate qualifications under applicable blue sky or other state securities laws, and appropriate
compliance with the Securities Act) as would permit or facilitate the sale and distribution of all or such portion of such Registrable Securities as are specified in such request, together with all or such portion of the Registrable Securities of
any Holder or Holders joining in such request as are specified in a written request received by the Company within twenty (20) days after such written notice from the Company is mailed or delivered. 

The Company will not be obligated to effect, or to take any action to effect, any such registration pursuant to this Section 1.3:

 (A) in any particular jurisdiction in which the Company would be required to execute a general consent to service of process
in effecting such registration, qualification, or compliance, unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act; 

(B) after the Company has initiated two (2) such registrations pursuant to Section 1.3(a) (counting for these purposes only
registrations which have been declared or ordered effective and registrations which have been withdrawn by the Holders as to which the Holders have not elected to bear all the Registration Expenses relating to such registration); 

(C) during the period starting with the date ninety (90) days prior to the Company’s good faith estimate of the date of
filing, and ending on a date one hundred eighty (180) days after the effective date, of a Company-initiated registration; provided, however, that the Company is actively employing in good faith all reasonable efforts to cause such registration
statement to become effective; and provided further that the Company uses commercially reasonable efforts to give notice to all Holders upon commencement of such period (and in any event, no later than thirty (30) days from the date the Company
receives a registration request from Initiating Holders as provided for in Section 1.3(a)); 
 (D) if the Initiating
Holders propose to dispose of shares of Registrable Securities which may be immediately registered on Form S-3 pursuant to a request made under Section 1.5 hereof. 

  
 -5-

 In the event that a withdrawal of a registration by the Holders is based upon material adverse information
relating to the Company that is different from the information made available (upon request from the Company or otherwise) to the Holders requesting registration at the time of their request for registration under this Section 1.3, such
registration will not be treated as a counted registration for purposes of this Section 1.3 hereof. 
 (b) Subject to the
foregoing clauses (A) through (D), the Company will file a registration statement covering the Registrable Securities so requested to be registered as soon as practicable after receipt of the request or requests of the Initiating Holders;
provided, however, that if (i) in the good faith judgment of the Board of Directors of the Company, such registration would be materially detrimental to the Company and the Board of Directors of the Company concludes, as a result, that it is
essential to defer the filing of such registration statement at such time, and (ii) the Company will furnish to such Holders a certificate signed by the President or Chief Executive Officer of the Company stating that in the good faith judgment
of the Board of Directors of the Company, it would be materially detrimental to the Company for such registration statement to be filed in the near future and that it is, therefore, essential to defer the filing of such registration statement, then
the Company will have the right to defer such filing for a period of not more than ninety (90) days after receipt of the request of the Initiating Holders, and, provided further, that the Company will not defer its obligation in this manner
more than once in any rolling twelve (12) month period. 
 The registration statement filed pursuant to the request of the
Initiating Holders may, subject to the provisions of Sections 1.3(b), 1.3(d), and 1.3(e) hereof, include other securities of the Company, with respect to which registration rights have been granted and may include securities of the Company being
sold for the account of the Company. 
 (c) If the Initiating Holders intend to distribute the Registrable Securities covered by
their request by means of an underwriting, they shall so advise the Company as a part of their request made pursuant to this Section 1.3, and the Company shall include such information in the written notice given pursuant to
Section 1.3(a)(i). In such event, the right of any Holder to include all or any portion of its Registrable Securities in such registration pursuant to this Section 1.3 shall be conditioned upon such Holder’s participation in an
underwriting and the inclusion of such Holder’s Registrable Securities to the extent provided herein. 
 (d) If the Company
will request inclusion in any registration pursuant to Section 1.3 of securities being sold for its own account, or if other persons will request inclusion in any registration pursuant to Section 1.3, the Initiating Holders will, on behalf
of all Holders, offer to include such securities in the underwriting and may condition such offer on their acceptance of the further applicable provisions of this Section 1. The Company will (together with all Holders and other persons
proposing to distribute their securities through such underwriting) enter into an underwriting agreement in customary form with the representative of the underwriter or underwriters selected for such underwriting by the Initiating Holders, to which
the Company has reasonably consented. 
 (e) Notwithstanding any other provision of this Section 1.3, if the representative
of the underwriters advises the Initiating Holders in writing that marketing factors require a limitation on the number of shares to be underwritten, the number of shares to be 

  
 -6-

 
included in the underwriting or registration will be allocated as set forth in Section 1.14 hereof. If a person who has requested inclusion in such registration as provided above does not
agree to the terms of any such underwriting, such person will be excluded therefrom by written notice from the Company, the underwriter or the Initiating Holders. The securities so excluded will also be withdrawn from registration. Any Registrable
Securities or other securities excluded or withdrawn from such underwriting will also be withdrawn from such registration. If shares are so withdrawn from the registration and if the number of shares to be included in such registration was
previously reduced as a result of marketing factors pursuant to this Section 1.3(e), then the Company will offer to all Holders who have retained rights to include securities in the registration the right to include additional securities in the
registration in an aggregate amount equal to the number of shares so withdrawn, with such shares to be allocated among such Holders requesting additional inclusion in accordance with Section 1.14. 

1.4 Company Registration. 
 (a) Whenever the Company proposes to register any of its securities either for its own account or the account of a security holder or holders exercising their respective demand registration rights (other
than pursuant to Sections 1.3 or 1.5 hereof), other than a registration relating solely to employee benefit plans or dividend reinvestment plans, or a registration relating to a corporate reorganization or other transaction under Rule 145, or a
registration on any registration form that does not permit secondary sales, the Company will: 
 (i) promptly give to each
Holder written notice thereof; and 
 (ii) use its best efforts to include in such registration (and any related qualification
under blue sky laws or other compliance), except as set forth in Section 1.4(b) below, and in any underwriting involved therein, all the Registrable Securities specified in a written request or requests, made by any Holder and received by the
Company within twenty (20) days after the written notice from the Company described in clause (i) above is mailed or delivered by the Company. Such written request may specify all or a part of a Holder’s Registrable Securities.

 (b) If the registration for which the Company gives notice is for a registered public offering involving an underwriting, the
Company will so advise the Holders as a part of the written notice given pursuant to Section 1.4(a)(i). In such event, the right of any Holder to registration pursuant to this Section 1.4 will be conditioned upon such Holder’s
participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting to the extent provided herein. All Holders proposing to distribute their securities through such underwriting will (together with
the Company and the other holders of securities of the Company with registration rights to participate therein distributing their securities through such underwriting) enter into an underwriting agreement in customary form with the representative of
the underwriter or underwriters selected by the Company. 
 Notwithstanding any other provision of this Section 1.4, if the
representative of the underwriters advises the Company in writing that marketing factors require a limitation on the number of shares to be underwritten, the representative may (subject to the limitations set forth below) exclude all Registrable
Securities from the Company’s initial public offering and reduce 

  
 -7-

 
the number of Registrable Securities to be included in any other registered offering of the Company; provided that Registrable Securities shall not be reduced to less than ten percent
(10%) of the total number of shares being registered in such other offering. If any Holder is unable to register shares of Registrable Securities in any offering other than the Company’s initial public offering as a result of the
limitations set forth in this Section 1.4(b), no Holders shall be permitted to register shares in such offering other than the Holders who initiated such registration in the case of a demand registration. The Company will so advise all holders
of securities requesting registration, and the number of shares of securities that are entitled to be included in the registration and underwriting will be allocated first to the Company for securities being sold for its own account and thereafter
as set forth in Section 1.14. If any person does not agree to the terms of any such underwriting or otherwise fails to comply with the provisions of this Agreement, he will be excluded therefrom by written notice from the Company or the
underwriter. Any Registrable Securities or other securities excluded or withdrawn from such underwriting will be withdrawn from such registration. 
 If shares are so withdrawn from the registration or if the number of Registrable Securities to be included in such registration was previously reduced as a result of marketing factors, the Company will
then offer to all persons who have retained the right to include securities in the registration the right to include additional securities in the registration in an aggregate amount equal to the number of shares so withdrawn, with such shares to be
allocated among the persons requesting additional inclusion in accordance with Section 1.14 hereof. 
 (c) The Company will
have the right to terminate or withdraw any registration initiated by it under this Section 1.4 prior to the effectiveness of such registration whether or not any Holder has elected to include securities in such registration. The Registration
Expenses of such withdrawn registration will be borne by the Company in accordance with Section 1.6 hereof. 
 1.5
Registration on Form S-3. 
 (a) After its initial public offering, the Company will use its best efforts to qualify for
registration on Form S-3 under the Securities Act or any comparable or successor form or forms. After the Company has qualified for the use of Form S-3, in addition to the rights contained in the foregoing provisions of this Section 1, Holders
of Registrable Securities will have the right to request registrations on Form S-3 (such requests will be in writing and will state the number of shares of Registrable Securities to be disposed of and the intended methods of disposition of such
shares by such Holder or Holders); provided, however, that the Company will not be obligated to effect any such registration: (i) if the Holders of Registrable Securities, together with the holders of any other securities of the Company
entitled to inclusion in such registration, propose to sell Registrable Securities and such other securities (if any) on Form S-3 at an aggregate price for each such offering to the public of less than Two Million Dollars ($2,000,000) (unless the
Holders of Registrable Securities hold, in the aggregate, stock with a value of less than Two Million Dollars ($2,000,000), in which such case, this restriction shall not apply); (ii) with respect to any rolling twelve (12) month period
if, during such period, the Company has effected two (2) such registrations (counting for these purposes only registrations which have been declared or ordered effective and registrations which have been withdrawn by the Holders as to which the
Holders have not elected to bear all the Registration Expenses 

  
 -8-

 
relating to such registration); (iii) in the event that the Company will furnish the certification described in paragraph 1.3(b) (but subject to the limitations set forth therein);
(iv) within one hundred eighty (180) days of the effective date of any other preceding Company registration statement (other than on Form S-8 or Form S-3 with respect to employees’ stock or a dividend reinvestment plan); or
(v) in any particular jurisdiction in which the Company would be required to qualify to do business or to execute a general consent to service of process in effecting such registration, qualification or compliance. 

(b) If a request complying with the requirements of Section 1.5(a) hereof is delivered to the Company, the provisions of Sections
1.3(a)(i) and (ii) and Section 1.3(b) (excluding reference to clauses (A) through (D) preceding such Section 1.3(b)) hereof will apply to such registration. If the registration is for an underwritten offering, the provisions
of Sections 1.3(c), 1.3(d), and 1.3(e) hereof (with the references to Section 1.3 therein deemed to refer to this Section 1.5) will in addition apply to such registration. 

1.6 Expenses of Registration. 
 All Registration Expenses incurred in connection with any registration, qualification or compliance pursuant to Sections 1.3, 1.4 and 1.5 hereof will be borne by the Company whether or not the
registration statement to which such Registration Expenses relate becomes effective; provided, however, that the Company will not be obligated to bear the Registration Expenses for more than two (2) registrations or qualifications made pursuant
to Section 1.3 hereof and two (2) registrations or qualifications made pursuant to Section 1.5 hereof; provided, further, that the Company shall not be required to pay for any expenses of any registration proceeding begun pursuant to
Sections 1.3 or 1.5 if the registration request is subsequently withdrawn at the request of the Initiating Holders or because a sufficient number of Holders shall have withdrawn so that the minimum offering conditions set forth in Sections
1.3(a) and 1.5(a)(i) are no longer satisfied (in which case all participating Holders shall bear such expenses pro rata among each other based on the number of Registrable Securities requested to be so registered), unless the
Initiating Holders agree to forfeit their right to a demand registration pursuant to clause (B) of Section 1.3; provided, further that if, at the time of such withdrawal, the Holders shall have learned of a material adverse change in the
condition, business, or prospects of the Company from that known to the Holders at the time of their request and have withdrawn the request with reasonable promptness after learning of such information then the Holders shall not be required to pay
any of such expenses and shall not forfeit their right to a demand registration pursuant to clause (B) of Section 1.3. All Selling Expenses relating to securities so registered will be borne by the holders of the securities being
registered pro rata on the basis of the number of shares of securities so registered on their behalf.  
 1.7
Registration Procedures. 
 In the case of each registration effected by the Company pursuant to Section 1 hereof, the
Company will keep each Holder advised in writing as to the initiation of each registration and as to the completion thereof. At its expense, the Company will use its best efforts to: 

  
 -9-

 (a) keep such registration effective for a period of one hundred fifty (150) days or
until the Holder or Holders have completed the distribution described in the registration statement relating thereto, whichever first occurs; provided, however, that (i) such one hundred fifty (150) day period will be extended for a period
of time equal to the period the Holder refrains from selling any securities included in such registration at the request of an underwriter of Common Stock (or other securities) of the Company; and (ii) in the case of any registration of
Registrable Securities on Form S-3 which are intended to be offered on a continuous or delayed basis, such one hundred fifty (150) day period will be extended, if necessary, to keep the registration statement effective until all such
Registrable Securities are sold, provided that Rule 415, or any successor rule under the Securities Act, permits an offering on a continuous or delayed basis, and provided further that applicable rules under the Securities Act governing the
obligation to file a post-effective amendment permit, in lieu of filing a post-effective amendment that (I) includes any prospectus required by Section 10(a)(3) of the Securities Act or (II) reflects facts or events representing a material
or fundamental change in the information set forth in the registration statement, the incorporation by reference of information required to be included in (I) and (II) above to be contained in periodic reports filed pursuant to Section 13
or 15(d) of the Exchange Act in the registration statement; 
 (b) prepare and file with the Commission such amendments and
supplements to such registration statement and the prospectus used in connection with such registration statement as may be necessary to comply with the provisions of the Securities Act with respect to the disposition of all securities covered by
such registration statement; 
 (c) furnish such number of prospectuses and other documents incident thereto, including any
amendment of or supplement to the prospectus, as a Holder from time to time may reasonably request; 
 (d) register and qualify
the securities covered by such registration statement under such other securities or Blue Sky laws of such jurisdiction as shall be reasonably requested by the Holders; provided, that the Company shall not be required in connection therewith
or as a condition thereto to qualify to do business or to file a general consent to service of process in any such states or jurisdictions. 
 (e) notify each seller of Registrable Securities covered by such registration statement at any time when a prospectus relating thereto is required to be delivered under the Securities Act of the
occurrence of any event as a result of which the prospectus included in such registration statement, as then in effect, includes an untrue statement of a material fact or omits to state a material fact required to be stated therein or necessary to
make the statements therein not misleading or incomplete in the light of the circumstances then existing, and at the request of any such seller, prepare and furnish to such seller a reasonable number of copies of a supplement to or an amendment of
such prospectus as may be necessary so that, as thereafter delivered to the purchasers of such shares, such prospectus will not include an untrue statement of a material fact or omit to state a material fact required to be stated therein or
necessary to make the statements therein not misleading or incomplete in the light of the circumstances then existing; 
 (f)
use its best efforts to cause all such Registrable Securities registered pursuant hereunder to be listed on each securities exchange or market on which similar securities issued by the Company are then listed, and enter into such customary
agreements including a listing application and indemnification agreement in customary form (provided that the applicable listing requirements are satisfied); 

  
 -10-

 (g) provide a transfer agent and registrar for all Registrable Securities registered
pursuant to such registration statement and a CUSIP number for all such Registrable Securities, in each case not later than the effective date of such registration; 
 (h) otherwise use its best efforts to comply with all applicable rules and regulations of the Commission, and make available to its security holders, as soon as reasonably practicable, an earnings
statement covering the period of at least twelve (12) months, but not more than eighteen (18) months, beginning with the first month after the effective date of the registration statement, which earnings statement will conform materially
with the provisions of Section 11(a) of the Securities Act; 
 (i) in connection with any underwritten offering pursuant to
a registration statement filed pursuant to Section 1.3 hereof, the Company will enter into an underwriting agreement in form reasonably necessary to effect the offer and sale of Common Stock, provided such underwriting agreement contains
customary underwriting provisions and provided further that if the underwriter so requests the underwriting agreement will contain customary contribution provisions; 
 (j) Make available for inspection during normal business hours by any Holder of Registrable Securities covered by such registration statement, any underwriter participating in any disposition pursuant to
such registration statement, and any attorney, accountant or other agent retained by any such Holder or underwriter (collectively, the “Inspectors”), all financial and other records, pertinent corporate documents and properties of
the Company and its subsidiaries (collectively, “Records”), if any, as shall be reasonably necessary to enable them to exercise their due diligence responsibility, and cause the Company’s and its subsidiaries’ officers,
directors and employees to supply all information and respond to all inquiries reasonably requested by any such Inspector in connection with such registration statement; provided, however, that the Company shall not be obligated to make available
for inspection or provide to a competitor of the Company information which the Board determines in good faith is proprietary information or make available or provide to such persons information under circumstances which the Company determines
disclosure thereof would result in a loss to the Company of attorney-client privilege. 
 (k) Comply, and continue to comply
during the period that such registration statement is effective under the Securities Act, in all material respects with the Securities Act and the Exchange Act and with all applicable rules and regulations of the Commission with respect to the
disposition of all securities covered by such registration statement, and not file any amendment or supplement to such registration statement or prospectus to which Holder shall have reasonably objected on the grounds that such amendment or
supplement does not comply in all material respects with the requirements of the Securities Act, having been furnished with a copy thereof at least five (5) business days prior to the filing thereof (with respect to any amendment) or at least
two (2) business days prior to the filing thereof (with respect to any supplement); and 

  
 -11-

 (l) furnish, at the request of a majority of the Holders participating in the registration,
on the date that such Registrable Securities are delivered to the underwriters for sale, if such securities are being sold through underwriters, or, if such securities are not being sold through underwriters, on the date that the registration
statement with respect to such securities becomes effective (i) an opinion, dated as of such date, of the counsel representing the Company for the purposes of such registration, in form and substance as is customarily given to the underwriters
in an underwritten public offering and reasonably satisfactory to a majority in interest of the Holders requesting registration, addressed to the underwriters, if any, and to the Holders requesting registration of Registrable Securities and
(ii) a letter dated as of such date from the independent certified public accountants of the Company, in form and substance as is customarily given by independent certified public accountants to underwriters in an underwritten public offering
and reasonably satisfactory to a majority in interest of the Holders requesting registration, addressed to the underwriters, if any, and if permitted by applicable accounting standards, to the Holders requesting registration of Registrable
Securities. 
 1.8 Indemnification. 
 (a) The Company will indemnify each Holder, each of such Holder’s officers, directors, managers, members, partners, legal counsel, and accountants and each person controlling such Holder within the
meaning of Section 15 of the Securities Act with respect to which registration, qualification, or compliance has been effected pursuant to this Section 1, and each underwriter, if any, and each person who controls within the meaning of
Section 15 of the Securities Act any underwriter, against all expenses, claims, losses, damages, and liabilities (or actions, proceedings or settlements in respect thereof) arising out of or based on any untrue statement (or alleged untrue
statement) of a material fact contained in any prospectus, offering circular or other document (including any related registration statement, notification, or the like) incident to any such registration, qualification, or compliance, or based on any
omission (or alleged omission) to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, or any material violation by the Company of the Securities Act or any rule or regulation
thereunder applicable to the Company and relating to action or inaction required of the Company in connection with any such registration, qualification, or compliance, and will reimburse each such Holder, each of its officers, directors, partners,
legal counsel, and accountants and each person controlling such Holder, each such underwriter, and each person who controls any such underwriter for any documented legal and other expenses reasonably incurred in connection with investigating and
defending or settling any such claim, loss, damage, liability, or action, provided that the Company will not be liable in any such case to the extent that any such claim, loss, damage, liability, or expense arises out of or is based on any untrue
statement or omission based upon written information furnished to the Company by such Holder or underwriter. It is agreed that the indemnity agreement contained in this Section 1.8(a) will not apply to amounts paid in settlement of any such
loss, claim, damage, liability, or action if such settlement is effected without the consent of the Company (which consent will not be unreasonably withheld). 
 (b) Each Holder will, if Registrable Securities held by such Holder are included in the securities as to which such registration, qualification, or compliance is being effected, severally and not jointly,
indemnify the Company, each of its directors, officers, partners, legal counsel, and accountants and each underwriter, if any, of the Company’s 

  
 -12-

 
securities covered by such a registration statement, each person who controls the Company or such underwriter within the meaning of Section 15 of the Securities Act, each other such Holder
and other stockholder of the Company, and each of their officers, directors, managers, members, partners, and each person controlling such Holder or other stockholder, against all expenses, claims, losses, damages and liabilities (or actions,
proceedings or settlements in respect thereof) arising out of or based on any untrue statement (or alleged untrue statement) of a material fact contained in any such registration statement, prospectus, offering circular or other document (including
any related registration statement, notification, or the like) incident to any such registration, qualification, or compliance, or based on any omission (or alleged omission) to state therein a material fact required to be stated therein or
necessary to make the statements therein not misleading, and will reimburse the Company and such Holders, other stockholders, directors, officers, managers, members, partners, legal counsel, and accountants, persons, underwriters, or control persons
for any legal or any other expenses reasonably incurred in connection with investigating and defending or settling any such claim, loss, damage, liability, or action, in each case to the extent but only to the extent that such untrue statement (or
alleged untrue statement) or omission (or alleged omission) is made in such registration statement, prospectus, offering circular, or other document in reliance upon and in conformity with written information furnished to the Company by such Holder
and stated to be specifically for use therein provided, however, that the obligations of such Holder hereunder will not apply to amounts paid in settlement of any such claims, losses, damages, or liabilities (or actions in respect thereof) if such
settlement is effected without the consent of such Holder (which consent will not be unreasonably withheld); and provided, further, that in no event will any indemnification obligation under this Section 1.8 exceed the net proceeds from the
offering received by such Holder. 
 (c) Each party entitled to indemnification under this Section 1.8 (the
“Indemnified Party”) will give notice to the party required to provide indemnification (the “Indemnifying Party”) promptly after such Indemnified Party has actual knowledge of any claim as to which indemnity may be
sought, and will permit the Indemnifying Party to assume the defense of such claim or any litigation resulting therefrom; provided, however, that counsel for the Indemnifying Party, who will conduct the defense of such claim or any litigation
resulting therefrom, will be approved by the Indemnified Party (whose approval will not unreasonably be withheld), and the Indemnified Party may participate in such defense at such party’s expense; and provided, further, that the failure of any
Indemnified Party to give notice as provided herein will not relieve the Indemnifying Party of its obligations under this Section 1, to the extent such failure is not prejudicial. No Indemnifying Party, in the defense of any such claim or
litigation, will, except with the consent of each Indemnified Party, consent to entry of any judgment or enter into any settlement that does not include as an unconditional term thereof the giving by the claimant or plaintiff to such Indemnified
Party of a release from all liability indemnified hereunder with respect to such claim or litigation. Each Indemnified Party will furnish such information regarding itself or the claim in question as an Indemnifying Party may reasonably request in
writing and as will be reasonably required in connection with the defense of such claim and litigation resulting therefrom. 

  
 -13-

 (d) If the indemnification provided for in this Section 1.8 is held by a court of
competent jurisdiction to be unavailable to an Indemnified Party with respect to any loss, liability, claim, damage, or expense referred to therein, then the Indemnifying Party, in lieu of indemnifying such Indemnified Party hereunder, will
contribute to the amount paid or payable by such Indemnified Party as a result of such loss, liability, claim, damage, or expense in such proportion as is appropriate to reflect the relative fault of the Indemnifying Party on the one hand and of the
Indemnified Party on the other in connection with the statements or omissions that resulted in such loss, liability, claim, damage, or expense as well as any other relevant equitable considerations. The relative fault of the Indemnifying Party and
of the Indemnified Party will be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission to state a material fact relates to information supplied by the Indemnifying Party or
by the Indemnified Party and the parties’ relative intent, knowledge, access to information, and opportunity to correct or prevent such statement or omission. 
 (e) Notwithstanding the foregoing, to the extent that the provisions on indemnification and contribution contained in the underwriting agreement entered into in connection with the underwritten public
offering are in conflict with the foregoing provisions, the provisions in the underwriting agreement will control. 
 (f) The
obligations of the Company and Holders under this Section 1.8 shall survive the completion of any offering of Registrable Securities in a registration statement under this Section 1, and otherwise. 

1.9 Information by Holder. 
 Each Holder of Registrable Securities will furnish to the Company such information regarding such Holder and the distribution proposed by such Holder as the Company may reasonably request in writing and
as will be reasonably required in connection with any registration, qualification, or compliance referred to in this Section 1. 
 1.10 Limitations on Subsequent Registration Rights. 
 From and after the
date of this Agreement, the Company will not, without the prior written consent of the holders of at least a majority of the issued and outstanding Preferred Shares of the Company (determined on an as-converted to Common Stock basis) and Common
Stock of the Company issued upon conversion of Preferred Shares, enter into any agreement with any holder or prospective holder of any securities of the Company giving such holder or prospective holder any registration rights. 

1.11 Rule 144 Reporting. 
 With a view to making available the benefits of certain rules and regulations of the Commission that may permit the sale of the Registrable Securities to the public without registration, the Company
agrees to use its best efforts to: 
 (a) make and keep public information regarding the Company available as those terms are
understood and defined in Rule 144 under the Securities Act, at all times from and after ninety (90) days following the effective date of the first registration under the Securities Act filed by the Company for an offering of its securities to
the general public; 

  
 -14-

 (b) file with the Commission in a timely manner all reports and other documents required of
the Company under the Securities Act and the Exchange Act at any time after it has become subject to such reporting requirements; and 
 (c) so long as a Holder owns any Registrable Securities, furnish to the Holder forthwith upon written request as to the Company’s compliance with the reporting requirements of Rule 144 (at any time
from and after ninety (90) days following the effective date of the first registration statement filed by the Company for an offering of its securities to the general public), and of the Securities Act and the Exchange Act (at any time after it
has become subject to such reporting requirements), a copy of the most recent annual or quarterly report of the Company, and such other reports and documents so filed as a Holder may reasonably request in availing itself of any rule or regulation of
the Commission allowing a Holder to sell any such securities without registration. 
 1.12 Delay of Registration; Furnishing
Information. 
 (a) No Holder will have any right to obtain or seek an injunction restraining or otherwise delaying any such
registration as the result of any controversy that might arise with respect to the interpretation or implementation of this Section 1. 
 (b) It will be a condition precedent to the obligations of the Company to take any action pursuant to Section 1.3, 1.4 or 1.5 as to any Holder that such selling Holder will furnish to the Company in
writing, within twenty (20) days after the Company’s written request, such information regarding himself, the Registrable Securities held by him and the intended method of disposition of such securities as will be required to effect the
registration of his Registrable Securities. 
 (c) No Holder may participate in any underwritten registration pursuant to this
Agreement unless such Holder completes and executes all questionnaires, powers of attorney, indemnities, underwriting agreements and other documents reasonably required by the terms of such underwriting arrangements. 

(d) Each Holder participating in a registration under this Agreement will agree to convert into shares of Common Stock that portion of
his shares of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock or Series E Preferred Stock to be registered pursuant to the corresponding registration prior to the effectiveness of the
corresponding registration; provided, however, such conversion may be conditioned on the closing of the offering contemplated by such registration statement. 
 1.13 Transfer or Assignment of Registration Rights. 
 The rights to cause
the Company to register securities granted to a Holder by the Company under this Section 1 may be transferred or assigned by a Holder only to a transferee or assignee of not less than fifty percent (50% of the Registrable Securities initially
issued to such Holder (subject to subsequent adjustments for stock splits, stock dividends, reverse stock splits, and the like); provided, however, that, (i) the Company is given written notice at the time of or within thirty (30) days
after transfer or assignment, stating the name and address of the transferee or assignee and identifying the securities with respect to which such registration rights are being 

  
 -15-

 
transferred or assigned, (ii) the transferee or assignee of such rights assumes in writing the obligations of such Holder under this Section 1, and (iii) the proposed transferee is
not, in the Company’s reasonable opinion, a competitor of the Company or a party who is demonstrably hostile towards the Company. Notwithstanding the foregoing, the transfer of registration rights to (a) any partner or retired partner or
member or former member of, or corporation, company, limited liability company, partnership, affiliated fund or other business entity which controls or is controlled by, or is under common control with, a Holder, (b) a family member of a Holder
or trust for the benefit of any individual Holder, (c) any other Investor who has such registration rights, or (d) as provided by restrictions required by law, will be without restriction, provided in each case that such the transferee or
assignee of such rights assumes in writing the obligations of such Holder under this Section 1. 
 1.14 Allocation of
Registration Opportunities. 
 In any circumstance in which all of the Registrable Securities and other shares of Common
Stock of the Company (including shares of Common Stock issued or issuable upon conversion of shares of any currently unissued series of Preferred Stock of the Company) with registration rights (the “Other Shares”) requested to be
included in a registration on behalf of the Holders or other selling stockholders cannot be so included as a result of limitations of the aggregate number of shares of Registrable Securities and Other Shares that may be so included, the number of
shares of Registrable Securities and Other Shares that may be so included will be allocated first to the Holders, then to any Other Stockholders requesting inclusion of shares, and then among the other selling stockholders requesting inclusion of
shares, in each case pro rata on the basis of the number of shares of Registrable Securities and Other Shares that would be held by such Holders and other selling stockholders, assuming conversion; provided, however, that such allocation will not
operate to reduce the aggregate number of Registrable Securities and Other Shares to be included in such registration, if any Holder or other selling stockholder does not request inclusion of the maximum number of shares of Registrable Securities
and Other Shares allocated to him pursuant to the above-described procedure, and the remaining portion of his allocation will be reallocated among those requesting Holders and other selling stockholders whose allocations did not satisfy their
requests pro rata on the basis of the number of shares of Registrable Securities and Other Shares which would be held by such Holders and other selling stockholders, assuming conversion, and this procedure will be repeated until all of the shares of
Registrable Securities and Other Shares which may be included in the registration on behalf of the Holders and other selling stockholders have been so allocated. The Company will not limit the number of Registrable Securities to be included in a
registration pursuant to this Agreement in order to include Other Shares or shares held by stockholders with no registration rights or any other shares of stock issued to employees or consultants pursuant to a Company Stock Option Plan, or, with
respect to registrations under Sections 1.3 or 1.5 hereof, in order to include in such registration securities registered for the Company’s own account. 
 1.15 Termination of Registration Rights. 
 The rights to request
registration of certain capital stock of the Company pursuant to Sections 1.3, 1.4 and 1.5 hereof will terminate as to any Holder on the earlier to occur of: (i) when such Holder holds one percent (1%) or less of the total issued and
outstanding shares of Common Stock (calculated on a fully diluted basis (as defined in the Third Amended and 

  
 -16-

 
Restated Investors’ Rights Agreement, dated as of the date hereof)), or (ii) when all of such Holder’s Registrable Securities may be sold or transferred under Rule 144 without the
need to comply with any current public information, manner of sale or filing requirements. Further, the rights of the parties pursuant to Sections 1.3, 1.4 and 1.5 hereof shall terminate upon the fourth anniversary of the Company’s initial
underwritten public offering pursuant to an effective registration statement under the Securities Act covering the offering and sale of capital stock for the account of the Company. 
 SECTION 2. MISCELLANEOUS. 
 2.1 Governing Law. 

This Agreement shall be governed by and construed under the laws of the State of Delaware without regard to conflicts of laws principles,
and shall be binding upon the parties hereto in the United States and worldwide. All disputes with respect to this Agreement shall be brought and heard either in the New York state courts located in New York County, New York, or the federal district
courts of New York. The parties to this Agreement each consent to the in personam jurisdiction and venue of such courts. The parties agree that service of process upon them in any such action may be made if delivered in person, by courier
service, by telegram, by telefacsimile or by first class mail, and shall be deemed effectively given upon receipt. 
 2.2
Successors and Assigns. 
 Except as otherwise expressly provided herein, the provisions hereof will inure to the benefit of,
and be binding upon, the successors, permitted assigns, heirs, executors and administrators of the parties hereto. 
 2.3
Entire Agreement; Amendment; Waiver. 
 This Agreement (including the Exhibits hereto) constitutes the full and entire
understanding and agreement between the parties with regard to the subject matter hereof and thereof. Neither this Agreement nor any term hereof may be amended, waived, discharged or terminated, except by a written instrument signed by the Company
and the holders of at least a majority of the Registrable Securities, and any such amendment, waiver, discharge or termination will be binding on all holders, but in no event will the obligation of any Holder hereunder be materially increased,
except upon the written consent of such Holder. 
 2.4 Notices. 

All notices and other communications required or permitted hereunder will be in writing and will be sent by facsimile or email or
delivered personally by hand or nationally recognized courier addressed (a) if to a Holder, to the address, facsimile number or email address indicated on the signature pages of this Agreement, or at such other address, facsimile number or
email address as such Holder or permitted assignee will have furnished to the Company in writing, or (b) if to the Company, to the address, facsimile number or email address indicated on the signature pages of this Agreement, or at such other
address, facsimile number or email address as the Company will have furnished to each such Holder in writing. All such notices and other written communications will be effective on the date of confirmed receipt of facsimile transmission, confirmed
receipt of email or delivery. 

  
 -17-

 2.5 Delays or Omissions. 

No delay or omission to exercise any right, power or remedy accruing to any Holder, upon any breach or default of the Company under this
Agreement will impair any such right, power or remedy of such Holder nor will it be construed to be a waiver of any such breach or default, or an acquiescence therein, or of or in any similar breach or default thereafter occurring; nor will any
waiver of any single breach or default be deemed a waiver of any other breach or default therefore or thereafter occurring. Any waiver, permit, consent or approval of any kind or character on the part of any Holder of any breach or default under
this Agreement or any waiver on the part of any Holder of any provisions or conditions of this Agreement must be made in writing and will be effective only to the extent specifically set forth in such writing. All remedies, either under this
Agreement or by law or otherwise afforded to any Holder, will be cumulative and not alternative. 
 2.6 Rights; Severability.

 Unless otherwise expressly provided herein, a Holder’s rights hereunder are several rights, not rights jointly held
with any of the other Holders. In case any provision of the Agreement will be invalid, illegal or unenforceable, the validity, legality and enforceability of the remaining provisions will not in any way be affected or impaired thereby. 

2.7 Information Confidential. 
 Each party acknowledges that the information received by them pursuant hereto may be confidential and for its use only, and it will not use such confidential information in violation of the Securities Act
or Exchange Act or reproduce, disclose or disseminate such information to any other person (other than its employees or agents having a need to know the contents of such information, and its attorneys, who are bound to conditions of confidentiality
with respect to such information), except in connection with the exercise of rights under this Agreement, unless the Company has made such information available to the public generally or such party is required to disclose such information by a
governmental body. 
 2.8 Titles and Subtitles. 
 The titles of the paragraphs and subparagraphs of this Agreement are for convenience of reference only and are not to be considered in construing or interpreting this Agreement. 

2.9 Counterparts. 
 This Agreement may be executed in any number of counterpart signature pages (including facsimile counterpart signature pages), each of which will be an original, but all of which, when taken together,
will constitute one and the same instrument. 

  
 -18-

 2.10 Attorneys’ Fees. 

In the event that any suit or action is instituted to enforce any provision in this Agreement, the prevailing party in such dispute shall
be entitled to recover from the losing party all fees, costs and expenses of enforcing any right of such prevailing party under or with respect to this Agreement, including without limitation, such reasonable fees and expenses of attorneys and
accountants, which shall include, without limitation, all fees, costs and expenses of appeals. 
 (The remainder of this page is
intentionally left blank. The signature page follows.) 

  
 -19-

 (Signature Page to Regado Biosciences, Inc. Registration Rights Agreement) 

IN WITNESS WHEREOF, the foregoing Third Amended and Restated Registration Rights Agreement is hereby executed by the undersigned as of
the date first above written. 
  

			
	 COMPANY:
  

REGADO BIOSCIENCES, INC.

		
	By:	 	/s/ David J. Mazzo
	Name:	 	David J. Mazzo, Ph.D.
	Title:	 	President and Chief Executive Officer

 (Signature Page to Regado Biosciences, Inc. Registration Rights Agreement) 

 

			
	 INVESTORS:
  

        RMI INVESTMENTS, S.Á R.L.

		
	        By:	 	Vladimir Gurdus
	        Its Director
		
	        By:	 	/s/ Vladimir Gurdus

 (Signature Page to Regado Biosciences, Inc. Registration Rights Agreement) 

 

			
	BAXTER HEALTHCARE CORPORATION
		
	By:	 	/s/ Norbert Riedel

 (Signature Page to Regado Biosciences, Inc. Registration Rights Agreement) 

 

			
	 DOMAIN PARTNERS VI, L.P.
  

By: One Palmer Square Associates VI, L.L.C.
 Its
General Partner

		
	By:	 	/s/ Kathleen Schoemaker
	Name:	 	Kathleen Shoemaker
	Title:	 	Managing Member

 (Signature Page to Regado Biosciences, Inc. Registration Rights Agreement) 

 

			
	 DP VI ASSOCIATES, L.P.
  

By: One Palmer Square Associates VI, L.L.C.
 Its
General Partner

		
	By:	 	/s/ Kathleen Schoemaker
	Name:	 	Kathleen Shoemaker
	Title:	 	Managing Member

 (Signature Page to Regado Biosciences, Inc. Registration Rights Agreement) 

 

			
	 QUAKER BIOVENTURES, L.P.
  

By: Quaker Bioventures Capital, L.P.
 Its General
Partner
  
 By: Quaker Bioventures Capital, LLC

Its General Partner

		
	By:	 	/s/ Sherrill Neff

 (Signature Page to Regado Biosciences, Inc. Registration Rights Agreement) 

 

			
	 AURORA VENTURES V, LLC
  

By: A.V. Management V, L.L.C,
 Its Managing
Member

		
	By:	 	/s/ B. Jefferson Clark
	Name:	 	B. Jefferson Clark
	Title:	 	Manager

 (Signature Page to Regado Biosciences, Inc. Registration Rights Agreement) 

 

			
	
	    /s/ Robert Kierlin
	Robert Kierlin, Individually

 (Signature Page to Regado Biosciences, Inc. Registration Rights Agreement) 

 

			
	 CAXTON ADVANTAGE LIFE SCIENCES FUND, L.P.

 
 By: Caxton Advantage Venture Partners, L.P.

Its General Partner
  
 By: Advantage Life Sciences Partners, LLC
 Its Managing General Partner

		
	By:	 	/s/ Eric Roberts
	Name:	 	Eric Roberts
	Title:	 	Member

 (Signature Page to Regado Biosciences, Inc. Registration Rights Agreement) 

 

			
	 BIODISCOVERY 3 FCPR
  

By: EDMOND DE ROTHSCHILD INVESTMENT
 PARTNERS, its management company

		
	By:	 	/s/ Raphael Wisniewski
	Name:	 	Raphael Wisniewski
	Title:	 	Directeur Associé

 (Signature page to Regado Biosciences, Inc. Registration Rights
Agreement) 
  

			
	 AURORA VENTURES IV, LLC
  

By: A.V. Management IV, L.L.C,
 Its Managing
Member

		
	By:	 	/s/ B. Jefferson Clark
	Name:	 	B. Jefferson Clark
	Title:	 	Manager

 SCHEDULE A 

Series A Investors 
 Aurora Ventures IV, LLC 
 Robert Kierlin 

Series B Investors 
 Domain Partners VI, L.P. 
 DP VI Associates, L.P. 

Quaker Bioventures, L.P. 
 Aurora Ventures IV, LLC 
 Robert Kierlin 

Robert M. Bonczek 

Jeffrey M. Lipton 

Matton Venture Partners V 
 Claude T. Moorman, III, M.D. 
 Series C Investors 

Domain Partners VI, L.P. 
 DP VI Associates, L.P. 
 Quaker Bioventures, L.P. 

Aurora Ventures IV, LLC 
 Robert Kierlin 
 Caxton Advantage Life Sciences Fund, L.P. 

Robert M. Bonczek 

Jeffrey M. Lipton 

Matton Venture Partners V 
 Claude T. Moorman, III, M.D. 
 Series D Investors 

Domain Partners VI, L.P. 
 DP VI Associates, L.P. 
 Quaker Bioventures, L.P. 

Aurora Ventures V, LP 
 Robert Kierlin 
 Caxton Advantage Life Sciences Fund, L.P. 

BioDiscovery 3 FCPR 

Christopher E. Courts 

 Series E Investors 

Domain Partners VI, L.P. 
 DP VI Associates, L.P. 
 Quaker Bioventures, L.P. 

Aurora Ventures V, LLC 
 Robert Kierlin 
 Caxton Advantage Life Sciences Fund, L.P. 

BioDiscovery 3 FCPR 

RMI Investments, S.Á.R.L. 
 Baxter Healthcare Corporation

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00216-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00216-of-00352.parquet"}]]